enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
enGene Holdings (Nasdaq: ENGN) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's Chief Strategy and Operations Officer, Dr. Alex Nichols, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 8:40 a.m. ET.
enGene is currently conducting a pivotal study of its non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, previously EG-70) for patients with high-risk, BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The presentation will be available via webcast on the company's website under the 'Investors' section and will remain accessible for 90 days.
enGene Holdings (Nasdaq: ENGN) ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulla Salute e Scienze della Vita di Oppenheimer. Il Chief Strategy and Operations Officer dell'azienda, il Dr. Alex Nichols, presenterà all'evento virtuale martedì 11 febbraio 2025, alle 8:40 a.m. ET.
enGene sta attualmente conducendo uno studio cruciale sul suo prodotto investigativo non virale principale detalimogene voraplasmid (noto anche come detalimogene, precedentemente EG-70) per pazienti con carcinoma della vescica non muscolo invasivo (NMIBC) a alto rischio e non responsivi al BCG, con carcinoma in situ (CIS). La presentazione sarà disponibile in streaming sul sito web dell'azienda nella sezione 'Investitori' e rimarrà accessibile per 90 giorni.
enGene Holdings (Nasdaq: ENGN) ha anunciado su participación en la 35ª Conferencia Anual de Salud y Ciencias de la Vida de Oppenheimer. El Director de Estrategia y Operaciones de la compañía, el Dr. Alex Nichols, realizará una presentación en el evento virtual el martes 11 de febrero de 2025, a las 8:40 a.m. ET.
enGene está llevando a cabo un estudio pivotal de su principal producto investigacional no viral detalimogene voraplasmid (también conocido como detalimogene, anteriormente EG-70) para pacientes con cáncer de vejiga no músculo invasivo (NMIBC) de alto riesgo y no respondedor al BCG, con carcinoma in situ (CIS). La presentación estará disponible a través de una transmisión en vivo en el sitio web de la compañía en la sección 'Inversores' y permanecerá accesible durante 90 días.
enGene Holdings (Nasdaq: ENGN)는 오펜하이머 제35회 연례 건강 및 생명 과학 콘퍼런스에 참여한다고 발표했습니다. 회사의 최고 전략 및 운영 책임자인 알렉스 니콜스 박사가 2025년 2월 11일 화요일 오전 8시 40분 ET에 가상 이벤트에서 발표를 진행할 예정입니다.
enGene은 현재 고위험, BCG 비반응성(non-muscle invasive) 방광암(NMIBC) 및 제자리암종(CIS) 환자를 위한 비 바이러스 기반의 주요 임상 시험 제품 detalimogene voraplasmid (이전 이름 EG-70) 연구를 진행하고 있습니다. 발표는 회사 웹사이트의 '투자자' 섹션에서 웹캐스트를 통해 제공되며, 90일 동안 접근할 수 있습니다.
enGene Holdings (Nasdaq: ENGN) a annoncé sa participation à la 35ème Conférence Annuelle sur la Santé et les Sciences de la Vie d'Oppenheimer. Le Directeur de la Stratégie et des Opérations de l'entreprise, Dr. Alex Nichols, fera une présentation lors de l'événement virtuel le mardi 11 février 2025, à 8h40 ET.
enGene mène actuellement une étude clé sur son produit d'investigation non viral principal detalimogene voraplasmid (également connu sous le nom de detalimogene, auparavant EG-70) pour les patients atteints de cancer de la vessie non invasif (NMIBC) à haut risque et non répondeurs au BCG, avec carcinome in situ (CIS). La présentation sera disponible par webdiffusion sur le site Web de l'entreprise dans la section 'Investisseurs' et restera accessible pendant 90 jours.
enGene Holdings (Nasdaq: ENGN) hat seine Teilnahme an der 35. Oppenheimer-Jahreskonferenz für Gesundheits- und Lebenswissenschaften bekannt gegeben. Der Chief Strategy and Operations Officer des Unternehmens, Dr. Alex Nichols, wird am Dienstag, den 11. Februar 2025, um 8:40 Uhr ET eine Präsentation auf der virtuellen Veranstaltung halten.
enGene führt derzeit eine entscheidende Studie zu seinem nicht-viralen Hauptforschungsprodukt detalimogene voraplasmid (auch bekannt als detalimogene, zuvor EG-70) für Patienten mit hochriskantem, BCG-resistentem, nicht-muskelinvasivem Blasenkarzinom (NMIBC) mit Krebs in situ (CIS) durch. Die Präsentation wird über einen Webcast auf der Website des Unternehmens im Bereich 'Investoren' verfügbar sein und für 90 Tage zugänglich bleiben.
- None.
- None.
A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid, (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) – a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204642828/en/
For media contact:
908-577-4531
mediainquiries@grcomms.com
For investor contact:
investors@engene.com
Source: enGene Holdings Inc.
FAQ
When is enGene (ENGN) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access enGene's (ENGN) Oppenheimer Conference presentation?
What is the current clinical focus of enGene's (ENGN) detalimogene voraplasmid?
Who will represent enGene (ENGN) at the 2025 Oppenheimer Healthcare Conference?
